I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
immunomodulators
stage iv nsclc
measurable disease
metastatic malignant solid tumor
BRAF
- 0 views
- 19 Feb, 2024